^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CPT

i
Other names: CPT, human recombinant circularly permuted TRAIL, human recombinant Apo2L/TRAIL
Associations
Trials
Company:
Beijing Sunbio Biotech
Drug class:
TRAIL R2 agonist, TRAIL R1 agonist
Associations
Trials
1year
Synergistic antitumor effects of circularly permuted TRAIL with doxorubicin in triple-negative breast cancer. (PubMed, Acta Biochim Biophys Sin (Shanghai))
Collectively, our findings demonstrate that treatment with CPT in combination with Dox exerts synergistic antitumor effects through activation of the caspase cascade pathway, a mechanism that is partly dependent on the Dox-induced upregulation of death receptor 4 and death receptor 5. Therefore, CPT combined with Dox may be a feasible therapeutic strategy for the management of TNBC.
Journal • PARP Biomarker
|
CASP3 (Caspase 3) • CASP8 (Caspase 8) • TNFRSF10B (TNF Receptor Superfamily Member 10b)
|
doxorubicin hydrochloride • CPT